Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Post by Jefferam1on Sep 05, 2018 10:35am

123 Views

Post# 28565078

Part 1

With another re-iteration of : Antibe will be commencing a Phase 2B dose-ranging, efficacy study this month.
being only 3.5 weeks left in the month, you'd think they can't get that wrong now.
I'm really hoping they have no more slippage of timelines.
In about 3 months we should have the start of Part 2, that will be exciting times.
As that trial starts, thats when things should really start to progress in my mind.

Bullboard Posts

Debt-free cannabis company set for next stage of growth